| Improving efficacy of cancer immunotherapy by genetic modification of natural killer cells RA Burga, T Nguyen, J Zulovich, S Madonna, L Ylisastigui, R Fernandes, ... Cytotherapy 18 (11), 1410-1421, 2016 | 36 | 2016 |
| Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections. Aarons,, EM Fernandez, A Rees, M McClure, and, J Weber, ... HIV and the Pathogenesis of AIDS, Third Edition 11, 688-689., 2007 | | 2007 |
| Chemotactic activity of HIV-1 Nef for human monocytes MH Lehmann, S Walter, L Ylisastigui, F Striebel, V Ovod, M Geyer, ... Retrovirology 3 (Suppl 1), S70, 2006 | | 2006 |
| Extracellular HIV-1 Nef increases migration of monocytes MH Lehmann, S Walter, L Ylisastigui, F Striebel, V Ovod, M Geyer, ... Experimental cell research 312 (18), 3659-3668, 2006 | 31 | 2006 |
| Mitogen-activated protein kinases regulate LSF occupancy at the human immunodeficiency virus type 1 promoter L Ylisastigui, R Kaur, H Johnson, J Volker, G He, U Hansen, D Margolis Journal of virology 79 (10), 5952-5962, 2005 | 28 | 2005 |
| Polyamides reveal a role for repression in latency within resting T cells of HIV-infected donors L Ylisastigui, JJ Coull, VC Rucker, C Melander, RJ Bosch, SJ Brodie, ... The Journal of infectious diseases 190 (8), 1429-1437, 2004 | 71 | 2004 |
| Interleukin-7 induces HIV type 1 outgrowth from peripheral resting CD4+ T cells G Lehrman, L Ylisastigui, RJ Bosch, DM Margolis JAIDS Journal of Acquired Immune Deficiency Syndromes 36 (5), 1103-1104, 2004 | 44 | 2004 |
| Targeting reservoirs of human immunodeficiency virus infection: inducing latent viral expression without host cell activation DM Margolis, G Lehrman, NM Archin, L Ylisastigui, MB Kvanli, D Turner, ... ANTIVIRAL THERAPY 9 (4), U63-U63, 2004 | | 2004 |
| Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression L Ylisastigui, NM Archin, G Lehrman, RJ Bosch, DM Margolis Aids 18 (8), 1101-1108, 2004 | 317 | 2004 |
| Coaxing human immunodeficiency virus type 1 from resting CD4+ T cells: can the reservoir of HIV be purged L Ylisastigui, N Archin, G Lehrman, RJ Bosch, DM Margolis AIDS 18 (8), 1101-1108, 2004 | 18 | 2004 |
| The regulation of HIV-1 gene expression: the emerging role of chromatin G He, L Ylisastigui, DM Margolis DNA and cell biology 21 (10), 697-705, 2002 | 66 | 2002 |
| The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in … DM Margolis, S Kewn, JJ Coull, L Ylisastigui, D Turner, H Wise, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 31 (1), 45-49, 2002 | 108 | 2002 |
| Synthesis and characterization of biologically functional biotinylated RANTES C Vita, E Drakopoulou, L Ylisastigui, Y Bakri, J Vizzavona, L Martin, ... Journal of immunological methods 266 (1-2), 53-65, 2002 | 22 | 2002 |
| CD40-activated macrophages become highly susceptible to X4 strains of human immunodeficiency virus type 1 Y Bakri, A Mannioui, L Ylisastigui, F Sanchez, JC Gluckman, A Benjouad AIDS research and human retroviruses 18 (2), 103-113, 2002 | 18 | 2002 |
| Host factors that down regulate HIV LTR expression may establish or maintain quiescent infection in T cells DM Margolis, L Ylisastigui, A Wozniakowski, H Johnson, V Rucker, ... ANTIVIRAL THERAPY 7, S76-S76, 2002 | | 2002 |
| Rational engineering of a miniprotein inhibitor of HIV-1 infectivity C Vita, E Drakopoulou, J Vizzavona, S Rochette, L Martin, A Ménez, ... Peptides for the New Millennium: Proceedings of the 16 th American Peptide …, 2002 | | 2002 |
| Soluble glycosaminoglycans do not potentiate RANTES antiviral activity on the infection of primary macrophages by human immunodeficiency virus type 1 L Ylisastigui, Y Bakri, S Amzazi, JC Gluckman, A Benjouad Virology 278 (2), 412-422, 2000 | 16 | 2000 |
| Rational engineering of a miniprotein inhibitor of HIV-1 infectivity CVE Drakopoulou, J Vizzavona, S Rochette, L Martin, A Menez, ... PEPTIDES-AMERICAN SYMPOSIUM- 16, 516-518, 2000 | | 2000 |
| In-vivo delivery of therapeutic proteins by genetically-modified cells: comparison of organoids and human serum albumin alginate-coated beads E Shinya, X Dervillez, F Edwards-Levy, V Duret, E Brisson, L Ylisastigui, ... Biomedicine & pharmacotherapy 53 (10), 471-483, 1999 | 61 | 1999 |
| Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein C Vita, E Drakopoulou, J Vizzavona, S Rochette, L Martin, A Ménez, ... Proceedings of the National Academy of Sciences 96 (23), 13091-13096, 1999 | 220 | 1999 |
